In May 2026, the FDA approved Guardant Health’s Guardant360 Liquid CDx, a next-generation blood-based genomic profiling assay that significantly expands the scope of liquid biopsy testing in oncology.
The newly approved blood-based genomic test expands coverage from 74 genes to more than 740 genes, a nearly 100-fold increase versus Guardant’s earlier Guardant360 CDx approved in 2020. This broader profiling capability is expected to strengthen physicians’ ability to identify actionable mutations and personalize cancer treatment pathways.
Key strategic implications:
· Expanded clinical utility:
Broader genomic coverage enhances the likelihood of detecting clinically relevant biomarkers, supporting more targeted therapy selection across oncology indications.
· Companion diagnostics advantage:
The FDA transferred all 7 companion diagnostic approvals from the legacy assay to the new platform, accelerating adoption while preserving clinical continuity.
· Potential pricing upside:
Analysts estimate the FDA-approved assay could achieve an Advanced Diagnostic Laboratory Test (ADLT) reimbursement price between $6,000 – $9,000, versus the current $5,000 benchmark.
Some projections even indicate a potential $9,700 list price.
· Revenue acceleration opportunity:
TD Cowen analysts project a 9% upside to Guardant’s 2027 revenues, driven by higher reimbursement and migration of existing LDT users to the FDA-approved assay.
Competitive Positioning:
Despite increasing competition from players such as Roche’s Foundation Medicine, Guardant is estimated to retain more than 50% market share in the liquid biopsy space.
Why this matters for the diagnostics industry:
This approval reflects a broader industry shift toward:
· Comprehensive genomic profiling
· Regulatory-backed liquid biopsy adoption
· Higher-value precision diagnostics
· Expanded reimbursement frameworks
As oncology care increasingly moves toward minimally invasive and data-driven testing models, FDA-approved liquid biopsy platforms could become central to next-generation cancer management strategies.